bone marrow metastases
Recently Published Documents


TOTAL DOCUMENTS

151
(FIVE YEARS 17)

H-INDEX

21
(FIVE YEARS 1)

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Yilin Huang ◽  
Jianpeng Cao ◽  
Dengsai Peng ◽  
Huipan Liu ◽  
Yue Chen

Author(s):  
Carlos De Miguel Sánchez ◽  
Diego Robles de Castro ◽  
Ana Isabel Córdoba Alonso ◽  
José María Guinea de Castro

Author(s):  
Lima Arya ◽  
Deepak Sundriyal ◽  
Rekha Bhandari ◽  
Ruchi Srivastava ◽  
Amit Sehrawat

2021 ◽  
Vol 0 (0) ◽  
pp. 0
Author(s):  
ArvindKumar Gupta ◽  
Shruti Agrawal ◽  
Rekha Bhandari ◽  
VinayN Gowda ◽  
Amit Gupta ◽  
...  

2020 ◽  
Author(s):  
Shruti Agrawal ◽  
Rekha Bhandari ◽  
Vinay N Gowda ◽  
Amit Gupta ◽  
Neha Singh ◽  
...  

AbstractBackgroundBone marrow metastasis is a significant presentation of many non-hematological malignancies. The present study was conducted with the aim of analysing the clinical, hematological and biochemical parameters of the patients with bone marrow metastases and to determine the parameters which could be possible indicators of bone marrow metastases.Material and methodsBone marrow aspirate, imprint and biopsy slides of 22 cases with bone marrow metastases were reviewed and the hematological and biochemical data of all these cases was compared with that of 20 controls who had no evidence of metastases.ResultsThe mean values of mean platelet volume (MPV), neutrophil to lymphocyte ratio (NLR) and serum lactate dehydrogenase (LDH) were found to be significantly different (p<0.001) between the cases and controls. A MPV<8.1 fL, NLR>3.5 and LDH>452 U/L showed high likelihood ratio in predicting bone marrow metastases.ConclusionParameters such as MPV, NLR and LDH can be used as efficient and easily available means to predict bone marrow metastasis for an early diagnosis.


2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii120-ii120
Author(s):  
Brad Clifton ◽  
Mark Anderson

Abstract Medulloblastoma is the most common primary brain tumor in children, but is rare in adults. Because of the scarcity of adult medulloblastoma cases, treatment guidelines in the adult population are not well established, especially regarding surveillance and treatment of recurrent disease. A 47-year-old African American male presented with one month of progressive unsteady gait and dizziness. Imaging revealed a posterior fossa mass and the patient underwent gross total resection. Histology confirmed medulloblastoma and molecular subtyping revealed Sonic Hedgehog (Shh) pathway activation. No metastases were found at the time of diagnosis, and the patient received adjuvant craniospinal radiation therapy. Three years later the patient developed low back pain with severe sciatica affecting his gait and pancytopenia. Imaging revealed diffuse osseous disease without CNS recurrence and bone marrow biopsy confirmed recurrent medulloblastoma. The patient subsequently began reduced chemotherapy consisting of cisplatin and etoposide because of his severe pancytopenia. Due to a lack of response after 4 cycles, the SMO antagonist vismodegib was added. Follow-up imaging revealed improvement/stability of osseous disease, lab work demonstrated resolution of pancytopenia, and repeat bone marrow was without malignancy. Vismodegib was continued as maintenance therapy. Six months after completion of cisplatin/etoposide, follow-up imaging revealed progression of metastatic disease. Shh activated medulloblastomas have demonstrated responses to SMO inhibition. However, these responses are often transient secondary to rapid development of resistance, but may have a role to play in patients who have bone marrow involvement that limits use of cytotoxic therapy or bone marrow transplant. Due to poor survival outcomes associated with bone marrow metastases, aggressive screening for bone marrow metastases at diagnosis and in surveillance should be considered.


2020 ◽  
Author(s):  
Daria Lazic ◽  
Florian Kromp ◽  
Michael Kirr ◽  
Filip Mivalt ◽  
Fikret Rifatbegovic ◽  
...  

ABSTRACTBone marrow commonly serves as a metastatic niche for disseminated tumor cells (DTCs) of solid cancers in patients with unfavorable clinical outcome. Single-cell assessment of bone marrow metastases is essential to decipher the entire spectrum of tumor heterogeneity in these cancers, however, has previously not been performed.Here we used multi-epitope-ligand cartography (MELC) to spatially profile 20 biomarkers and assess morphology in DTCs as well as hematopoietic and mesenchymal cells of eight bone marrow metastases from neuroblastoma patients. We developed DeepFLEX, a single-cell image analysis pipeline for MELC data that combines deep learning-based cell and nucleus segmentation and overcomes frequent challenges of multiplex imaging methods including autofluorescence and unspecific antibody binding.Using DeepFLEX, we built a single-cell atlas of bone marrow metastases comprising more than 35,000 single cells. Comparisons of cell type proportions between samples indicated that microenvironmental changes in the metastatic bone marrow are associated with tumor cell infiltration and therapy response. Hierarchical clustering of DTCs revealed multiple phenotypes with highly diverse expression of markers such as FAIM2, an inhibitory protein in the Fas apoptotic pathway, which we propose as a complementary marker to capture DTC heterogeneity in neuroblastoma.The presented single-cell atlas provides first insights into the heterogeneity of human bone marrow metastases and is an important step towards a deeper understanding of DTCs and their interactions with the bone marrow niche.


Sign in / Sign up

Export Citation Format

Share Document